不良研究所

Our President and COO Kathryn Corzo talks with editor Brian Buntz from Drug Discovery & Development.

Partnership to build a platform for the development of safer and more efficient genetic engineering of human cells for cell therap...

不良研究所 received a gold award for its participation in the Green Impact awards for sustainability.

BlueRock Therapeutics and 不良研究所 announce collaboration and option agreement for the discovery & manufacture of regulatory T cell...

In this episode of the SynBioBeta podcast, 不良研究所 CEO Mark Kotter discusses the influence synthetic biology is having on the futu...

不良研究所 secures foundational United States patent for opti-ox, its cell programming technology that uses genomic safe harbour site...

不良研究所's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.

An article on synbio in the Summer 2023 issue of Science in Parliament magazine. Authored by our founder and CEO Mark Kotter.